Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-15 in 3mo
ESTIMATED |
READOUT
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With
Phase 3 · Endometrial Neoplasms |
Merck Sharp & Dohme LLC | Pembrolizumab, Carboplatin, Paclitaxel, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|